Similar Search Results

Expected Profits and The Scientific Novelty of Innovation

Dranove, David - 2020

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10012481677

The NBER Orange Book Dataset : A User's Guide

Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa … - National Bureau of Economic Research - 2022

This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....

Persistent link: https://www.econbiz.de/10013462677

Can Operation Warp Speed Serve as a Model for Accelerating Innovations Beyond COVID Vaccines?

D'Souza, Arielle; Hoyt, Kendall; Snyder, Christopher M.; … - National Bureau of Economic Research - 2024

Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...

Persistent link: https://www.econbiz.de/10015056157

The Role of Assets In Place : Loss of Market Exclusivity and Investment

Higgins, Matthew J. - 2020

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10012481442

Private and Social Returns to R&D : Drug Development and Demographics

Benmelech, Efraim; Eberly, Janice C.; Krieger, Joshua L.; … - National Bureau of Economic Research - 2021

Investment in intangible capital--in particular, research and development--increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...

Persistent link: https://www.econbiz.de/10012482573

The Future of Drug Development : The Economics of Pharmacogenomics

Vernon, John A. - 2005

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...

Persistent link: https://www.econbiz.de/10012466796

The Cost of US Pharmaceutical Price Reductions : A Financial Simulation Model of R&D Decisions

Abbott, Thomas A. - 2005

Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have...

Persistent link: https://www.econbiz.de/10012467571

Insurance Design and Pharmaceutical Innovation

Agha, Leila - 2020

This paper studies how insurance coverage policies affect incentives for pharmaceutical innovation. In the United …

Persistent link: https://www.econbiz.de/10012481418

Organizing Crisis Innovation : Lessons from World War II

Gross, Daniel P. - 2020

World War II innovation model in other crises. In this essay we describe exactly how it worked. We do so first through a … general overview of how OSRD approached several questions that may confront any crisis innovation effort: priority setting … innovation policy different, how crisis innovation policy approaches may vary, and the limits to generalizing from World War II …

Persistent link: https://www.econbiz.de/10012482128

Price Indices and the Value of Innovation with Heterogenous Patients

Lucarelli, Claudio; Nicholson, Sean; Tilipman, Nicholas - National Bureau of Economic Research - 2021

justify high prices for the population as a whole, innovation improves the welfare of sicker, late-stage cancer patients. A …

Persistent link: https://www.econbiz.de/10012482551